Search Results - "Athyros, Vasilios G."

Diabetic Nephropathy: New Risk Factors and Improvements in Diagnosis by Tziomalos, Konstantinos, Athyros, Vasilios G

“…Diabetic nephropathy is the leading cause of end-stage renal disease. Patients with diabetic nephropathy have a high cardiovascular risk, comparable to…”
Get full text

The Pathogenetic Role of Cortisol in the Metabolic Syndrome: A Hypothesis by Anagnostis, Panagiotis, Athyros, Vasilios G., Tziomalos, Konstantinos, Karagiannis, Asterios, Mikhailidis, Dimitri P.

“…Context: The metabolic syndrome (MetS) is a cluster of metabolic abnormalities that increase the risk for type 2 diabetes mellitus and vascular disease. The…”
Get full text

Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update by Athyros, Vasilios G, Tziomalos, Konstantinos, Katsiki, Niki, Doumas, Michael, Karagiannis, Asterios, Mikhailidis, Dimitri P

“…Non-alcoholic fatty liver disease (NAFLD) is considered to be an independent cardiovascular disease (CVD) risk factor. However, simple steatosis has a benign…”
Get full text

Nonalcoholic fatty liver disease and statins by Tziomalos, Konstantinos, Athyros, Vasilios G, Paschos, Paschalis, Karagiannis, Asterios

“…Abstract Objective Nonalcoholic fatty liver disease (NAFLD) is the most frequent cause of elevated transaminase levels and affects approximately one third of…”
Get full text

Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis by Athyros, Vasilios G, MD, Tziomalos, Konstantinos, MD, Gossios, Thomas D, MD, Griva, Theodora, MD, Anagnostis, Panagiotis, MD, Kargiotis, Konstantinos, MD, Pagourelias, Efstathios D, MD, Theocharidou, Eleni, MD, Karagiannis, Asterios, Prof, Mikhailidis, Dimitri P, Dr

“…Summary Background Long-term statin treatment reduces the frequency of cardiovascular events, but safety and efficacy in patients with abnormal liver tests is…”
Get full text

Abnormal Peri-Organ or Intra-organ Fat (APIFat) Deposition: An Underestimated Predictor of Vascular Risk? by Katsiki, Niki, Athyros, Vasilios G, Mikhailidis, Dimitri P

“…Adipose tissue, a major endocrine organ, consists of brown and white adipocytes. Brown fat may play a beneficial role in cardiometabolic disorders. Brown…”
Get more information

Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk by Athyros, Vasilios G, Boutari, Chrysa, Stavropoulos, Konstantinos, Anagnostis, Panagiotis, Imprialos, Konstantinos P, Doumas, Michael, Karagiannis, Asterios

“…Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease (30% of the general population) and up to 40% of cases advance to the more severe…”
Get more information

Sexual Dysfunction, Cardiovascular Risk and Effects of Pharmacotherapy by Imprialos, Konstantinos P, Stavropoulos, Konstantinos, Doumas, Michael, Tziomalos, Konstantinos, Karagiannis, Asterios, Athyros, Vasilios G

“…Sexual dysfunction affects millions of people with an increasing prevalence, worldwide. The pathophysiology of the disease shares several similarities with…”
Get more information

A Pilot Study Suggesting Several Benefits of Alpha Lipoic Acid in Patients with Diabetes by Vasilios, Athyros G, George, Sfikas, Charalambos, Koumaras, Valasia, Athyrou

Get more information

Lipid-lowering treatment in peripheral artery disease by Katsiki, Niki, Giannoukas, Athanasios D, Athyros, Vasilios G, Mikhailidis, Dimitri P

“…•Peripheral artery disease (PAD) is characterized by increased cardiovascular risk.•Statins remain the first-line lipid-lowering therapy to treat PAD…”
Get full text

Nonalcoholic Fatty Liver Disease vs. Nonalcoholic Steatohepatitis: Pathological and Clinical Implications by Boutari, Chrysoula, Lefkos, Petros, Athyros, Vasilios G, Karagiannis, Asterios, Tziomalos, Konstantinos

“…The implications and prognosis of nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH) are substantially different. The aim of the present…”
Get more information

Metabolic syndrome and non-cardiac vascular diseases: an update from human studies by Katsiki, Niki, Athyros, Vasilios G, Karagiannis, Asterios, Mikhailidis, Dimitri P

“…The metabolic syndrome (MetS) is characterized by a cluster of risk factors including central obesity, hypertension, dyslipidemia and insulin resistance, The…”
Get more information

Hyperuricaemia and non-alcoholic fatty liver disease (NAFLD): a relationship with implications for vascular risk? by Katsiki, Niki, Athyros, Vasilios G, Karagiannis, Asterios, Mikhailidis, Dimitri P

“…Both elevated levels of uric acid and non-alcoholic fatty liver disease (NAFLD) have been associated with increased vascular risk. Furthermore, certain drugs…”
Get more information

The role of statins in the treatment of type 2 diabetes mellitus: an update by Katsiki, Niki, Athyros, Vasilios G, Karagiannis, Asterios, Mikhailidis, Dimitri P

“…The prevalence of type 2 diabetes mellitus (T2DM) is increasing worldwide. T2DM is associated with both microvascular (neuropathy, nephropathy and retinopathy)…”
Get more information

Exploring the Management of Statin Intolerant Patients: 2016 and Beyond by Katsiki, Niki, Athyros, Vasilios G, Karagiannis, Asterios

“…Statins remain the cornerstone of lipid-lowering treatment. They significantly reducing cardiovascular morbidity and mortality in primary and secondary…”
Get more information

Cardiovascular effects of sodium-glucose cotransporter 2 inhibitors: multiple actions by Katsiki, Niki, Athyros, Vasilios G., Mikhailidis, Dimitri P.

Get full text

Statins and Type 2 Diabetes Mellitus: An Update After 1 Year by Katsiki, Niki, Athyros, Vasilios G, Karagiannis, Asterios, Mikhailidis, Dimitri P

“…In a review [1] published in this journal in 2014 we updated the role of statin treatment in patients with type 2 diabetes mellitus (T2DM). This is an…”
Get more information

The Effect of Proprotein Convertase Subtilisin-Kexin Type 9 and its Inhibition on Glucose Metabolism and Cardiovascular Risk. We Should do Better the Second Time After Statins by Athyros, Vasilios G, Tziomalos, Konstantinos, Doumas, Michael, Sfikas, George, Karagiannis, Asterios

“…Statins remain the cornerstone of hypolipidaemic drug treatment. However, statins exert adverse effects on glucose metabolism. Given that new onset diabetes…”
Get more information

Inclisiran. A New Kid on the New Block for Treating Hypercholesterolaemia by Athyros, Vasilios G, Boutari, Chrysoula, Imprialos, Konstantinos, Doumas, Michael

Get more information

Ezetimibe therapy for dyslipidemia: an update by Katsiki, Niki, Theocharidou, Eleni, Karagiannis, Asterios, Athyros, Vasilios G, Mikhailidis, Dimitri P

“…Ezetimibe, an inhibitor of intestinal cholesterol absorption, can decrease total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), triglycerides…”
Get more information